Novel Drug Approvals for 2022 | FDA				
FDA-approved use on approval date*	**Approval Date**	**Active Ingredient**	**Drug Nan**	**No**
To treat prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer following other therapies	3/23/2022	lutetium (177Lu) vipivotide tetraxetan	Pluvicto	10.
To treat unresectable or metastatic melanoma	3/18/2022	nivolumab and relatlimab-rmbw	Opdualag	9.
To treat seizures in cyclin-dependent kinase-like 5 deficiency disorder	3/18/2022	ganaxolone	Ztalmy	8.
To treat intermediate or high-risk primary or secondary myelofibrosis in adults with low platelets	2/28/2022	pacritinib	Vonjo	7.
To treat hemolytic anemia in pyruvate kinase deficiency	2/17/2022	mitapivat	Pyrukynd	6.
To decrease the need for red blood cell transfusion due to hemolysis in cold agglutinin disease	2/4/2022	sutimlimab-jome	Enjaymo	5.
To treat neovascular (wet) aged-related macular degeneration and diabetic macular edema	1/28/2022	faricimab-svoa	Vabysmo	4.
To treat unresectable or metastatic uveal melanoma	1/25/2022	tebentafusp-tebn	Kimmtrak	3.
To treat refractory, moderate-to-severe atopic dermatitis	1/14/2022	abrocitinib	Cibinqo	2.
To treat insomnia	1/7/2022	daridorexant	Quviviq	1.
https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2022	رابط الموقع:			
د.أحمد المحمدي	إعداد: